



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

Sheet	1	of	15
-------	---	----	----

COMPLETE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
C8u		B1	EP 174,608			09/05/85		
		B2	EP 351,585			06/23/89		
		B3	EP 390,323			10/03/90		
C8u		B4	EP 475,623			08/23/91		
		B5	2,688,514		France (lang = French)	09/17/93	No Expl. Relevance	
		B6	JP 04-009338		Japanese Lang Doc	01/14/92	No Expl. Relevance	
C8u		B7	WO 90/05180			05/17/90		
	✓	B8	WO 90/10448			09/29/90		
	✓	B9	WO 91/15580			10/17/91		
	✓	B10	WO 93/03769			03/04/93		
	✓	B11	WO 93/19191			09/30/93		
C8u		B12	WO 93/25224			12/23/93		
		B13	WO 94/06910		Previously Cited	03/31/94	IDS (2 Dec 1996)	
C8u	✓	B14	WO 94/08026			04/14/94		
C8u		B15	WO 94/10323			05/11/94		
C8u		B16	WO 94/18992			09/01/94		
		B17	WO 94/24297		FRENCH LANG DOC.	10/27/94	No Expl. of Relevance	
C8u		B18	WO 94/26914			11/24/94		
		B19	WO 95/02697		French Lang Doc	01/26/95	No expl. of Relevance	
C8u		B20	WO 95/11301			04/27/95		


EXAMINER

low

DATE CONSIDERED

26 Nov 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

**COMPLETE IF KNOWN**

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset <i>et al.</i>
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

Sheet 2 of 15

**FOREIGN PATENT DOCUMENTS**

Foreign Patent or Application					
<del>B21</del>	<del>WO 95/11984</del>			05/04/95	
<del>B22</del>	<del>WO 95/14101</del>	French Lang Doc		05/26/95	No Expt. of Relevance
<del>B23</del>	<del>WO 95/14102</del>	French Lang Doc		05/26/95	No Expt. of Relevance
<del>B24</del>	<del>WO 95/23867</del>	French Lang Doc		09/08/95	No Expt. of Relevance
<del>B25</del>	<del>WO 95/30002</del>			11/09/95	
<del>B26</del>	<del>8 508879</del>	Japan (Japanese)		09/24/96	No Expt. of Relevance

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
esu	C1	ANDERSON, "Human Gene Therapy," <i>Nature</i> , 392:25-30, April 30, 1998.	
	C2	BACCHETTI <i>et al.</i> , "Inhibition of Cell Proliferation by and Adenovirus Vector Expressing the Human Wild Type p53 Protein," <i>International Journal of Oncology</i> , 3:781-788, 1993.	
	C3	BAKER <i>et al.</i> , "p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis," <i>Cancer Research</i> , 50:7717-7722, December 1990.	
	C4	BANDYOPADHYAY & TEMIN, "Expression of Complete Chicken thymidine Kinase Gene Inserted in a Retrovirus Vector," <i>Molecular and Cellular Biology</i> , 4(4):746-754, 1984.	
	C5	BOWTELL <i>et al.</i> , "Comparison of Expression in Hemopoietic Cells by Retroviral Vectors Carrying Two Genes," <i>Journal of Virology</i> , 62(7):2464-2473, 1988.	
	C6	BROWN <i>et al.</i> , "Increased Accumulation of p53 Protein in Cisplatin-Resistant Ovarian Cell Lines," <i>Int'l J. Cancer</i> , 55:678-684, 1993.	
	C7	BROWN <i>et al.</i> , "Mutant p53 Confers Cisplatin-Sensitivity to Resistant Ovarian Tumour Cells with Elevated Wild-Type p53," <i>Proc. Am. Assoc. Cancer Res.</i> , 34:355, Abstract #2116, 1993.	
	C8	CAI <i>et al.</i> , "Stable Expression of the Wild-Type p53 Gene in Human Lung Cancer Cells After Retrovirus-mediated Gene Transfer," <i>Hum. Gene Ther.</i> , 4:617-24, 1993.	
esu	C9	CARTER <i>et al.</i> , "Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency," <i>Virology</i> , 191:473-476, 1992.	


EXAMINER

Low

DATE CONSIDERED

26 mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjeret <i>et al.</i>
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02


MAR 26 2003

RECEIVED

TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
C8U	C10	CASEY <i>et al.</i> , "Growth Suppression of Human Breast Cancer Cells by the Introduction of a Wild-Type p53 Gene," <i>Oncogene</i> , 6:1791-1797, 1991.	
	C11	CASSON <i>et al.</i> , "p53 Gene Mutations in Barrett's Epithelium and Esophageal Cancer," <i>Cancer Research</i> , 51:4495-4499, 1991.	
	C12	CHANG <i>et al.</i> , "Inhibition of Intratracheal Lung Cancer Development by Systemic Delivery of E1A," <i>Oncogene</i> , 13:1405-1412, 1996.	
	C13	CHANG <i>et al.</i> , "Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-Type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy," <i>Arch Otolaryngol Head Neck Surg.</i> , 123:507-215, 1997.	
C8U	C14	COLICOS <i>et al.</i> , "Construction of a Recombinant Adenovirus Containing the <i>denV</i> Gene from Bacteriophage T4 Which Can Partially Restore the DNA Repair Deficiency in Xeroderma Pigmentosum Fibroblasts," <i>Carcinogenesis</i> , 12(2):249-255, 1991.	
	<del>C15</del>	<del>CONROY, "New Gene Therapy Cleared for Use Against Lung Cancer," <i>Biotech Daily</i>, pp. 3-4, September 18, 1992. Reference Not Provided</del>	
C8U	C16	DAVIDSON <i>et al.</i> , "A Model System for in Vivo Gene Transfer Into the Central Nervous System Using Adenoviral Vectors," <i>Nature Genetics</i> , 3:219-223, 1993.	
	C17	DEBUS <i>et al.</i> , "Effects of Antisense Oligodeoxynucleotides Complementary of mRNA of the Human c-Harvey-ras oncogene on Cell Proliferation" <i>J. Cancer Res. Clin. Oncol.</i> , 116 (Suppl Part 1):5-162, Abstract #A2.037.09, 1990.	
	C18	DELAUNEY <i>et al.</i> , "A Stable Bifunctional Antisense Transcript Inhibiting Gene Expression in Transgenic Plants," <i>Proc. Natl. Acad. Sci. USA</i> , 85:4300-4304, 1988.	
	C19	DONEHOWER, "Tumor Suppressor Gene p53 and Apoptosis," <i>Cancer Bull.</i> , 46(2):161-166, 1994.	
	C20	DORIGO <i>et al.</i> , "Sensitization of Rat Glioblastoma Multiforme to Cisplatin in Vivo Following Restoration of Wild-Type p53 Function," <i>J. Neurosurg.</i> , 88:595-540, 1998.	
C8U	C21	EAVES <i>et al.</i> , "The Biology of Normal and Neoplastic Stem Cells in CML," Chronic Myeloid Leukemia, 2 <sup>nd</sup> Int'l Conference, Bologna, Italy, October 4-7, 1992. From <i>Leukemia and Lymphoma</i> , 11:245-253, 1993.	

EXAMINER  low	DATE CONSIDERED  26 Mar 2003
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	


 <p align="center"><b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Form PTO-1449 (Modified) (Use several sheets if necessary)</p>		<b>COMPLETE IF KNOWN</b>	
		Application Number	08/335,461
		Confirmation Number	
		Filing Date	November 7, 1994
		First Named Inventor	Ruth Gjerset <i>et al.</i>
		Group Art Unit	1653
Examiner Name	Christopher S. F. Low		
Attorney Docket No.	54763.8001.US02		

Sheet 4 of 15

RECEIVED  
 MAR 26 2003  
 TECH CENTER 160012900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
122	C22	EL ROUBY <i>et al.</i> , "p53 Gene Mutation in B-cell Chronic Lymphocytic Leukemia is Associated With Drug Resistance and its Independent of MDR1/MDR3 Gene Expression," <i>Blood</i> , 82(11):3452-3459, 1993.	
	C23	EL-DEIRY <i>et al.</i> , "WAF1, A Potential Mediator of p53 Tumor Suppression," <i>Cell</i> , 75:817-825, 1993.	
	C24	ELIYAHU <i>et al.</i> , "p53 - A Potential Suppressor Gene?" <i>J. Cell. Biochem.</i> , UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 <sup>th</sup> Annual Meeting, Supplement 14C:264, #I 030, 1990.	
	C25	ELIYAHU <i>et al.</i> , "Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species," <i>Oncogene</i> , 3:313-321, 1988.	
	C26	ELIYAHU <i>et al.</i> , "Wild-Type p53 Can Inhibit Oncogene-Mediated Focus Formation," <i>Proc. Nat. Acad. Sci. USA</i> , 85:8763-8767, November 1989.	
	C27	FAN <i>et al.</i> , "p53 Gene Mutations are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents," <i>Cancer Res.</i> , 54(22):5824-5830, 1994.	
	C28	FEIG <i>et al.</i> , "Somatic Activation of K-ras Gene in a Human Ovarian Carcinoma," <i>Science</i> , 223:698-701, 1984.	
	C29	FELGNER <i>et al.</i> , "Lipfection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure," <i>Proc. Natl. Acad. Sci. USA</i> , 84:7413-7417, 1987.	
	C30	FINKEL <i>et al.</i> , "Activation of ras Genes in Human Tumors Does Not Affect Localization Modification, or Nucleotide Binding Properties of p21," <i>Cell</i> , 37:151:158, 1984.	
	C31	FINLAY <i>et al.</i> , "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093, June 1989.	
	C32	FORNACE, Jr., "Induction by Radiation of Mammalian Genes Associated with Growth-Arrest and Apoptosis, and the Role for the p53 Tumor Suppressor in Their Regulation," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:681-682, 1994.	
	C33	FOX, "Investigation of Gene Therapy Begins," <i>Nature Biotechnology</i> , 18:143-144, 2000.	
	C34	FRITSCH <i>et al.</i> , "Induction of Nuclear Accumulation of the Tumor-Suppressor Protein p53 by DNA-Damaging Agents," published erratum, <i>Oncogene</i> , 8:307-318, 1993.	

EXAMINER  <i>low</i>	DATE CONSIDERED  <i>26 Mar 2003</i>
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

TECH CENTER 1600/2800

MAR 26 2003

RECEIVED

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
<i>CSU</i>	C35	FUJIWARA et al., "Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-Mediated Transfer of the Wild-Type p53 Gene," <i>Cancer Res.</i> , 54:2287-2291, 1994.	
	C36	FUJIWARA et al., "A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis," <i>Cancer Res.</i> , 53:4129-4133, 1993.	
	C37	FUJIWARA et al., "Therapeutic Effect of a Retroviral Wild-Type p53 Expression Vector in an Orthotopic Lung Cancer Model," <i>J. Natl. Cancer Inst.</i> , 86(19):1458-1462, 1994.	
	C38	GEBHARDT et al., "A Tumor Suppressor Proto-Oncogene p53 Can Block Progression Through the Cell Cycle," Association of American Physicians, American Society for Clinical Investigation, American Federation for Clinical Research, Subspecialty Meetings, Sheraton Washington Hotel, Washington, DC, May 6, 1990, pg. 447A, Abstract.	
	C39	GEORGES et al., "Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct," <i>Cancer Research</i> , 53:1748-1746, 1993.	
<i>CSU</i>	C40	GJERSET et al., "Dominant Effect of Transduced Wild-Type p53 Over Endogenous Mutant p53 in Sensitizing Tumor Cells to Therapy," <i>Proceedings of the Am. Assoc. Can. Res.</i> , 36:21, 1995. (Abstract 123)	
	<del>C41</del>	<del>GOBE et al., "Cell Death By Apoptosis Following X-Irradiation of the Foetal and Neonatal Rat Kidney," <i>Intl. J. Radiat. Biol.</i>, 54:567-576, 1988. Reference Not Provided</del>	
<i>CSU</i>	C42	GOMEZ-FOIX et al., "Adenovirus-Mediated Transfer of the Muscle Glycogen Phosphorylase Gene into Hepatocytes Confers Altered Regulation of Glycogen Metabolism," <i>The Journal of Biological Chemistry</i> , 267(35):25129-28134, 1992.	
	C43	GOMEZ-NAVARRO et al., "Gene Therapy for <del>Cancer</del> <b>Cancer</b> ," <i>European Journal of Cancer</i> , 35:864-885, 1999.	
	C44	GOYETTE et al., "Progression of Colorectal Cancer is Associated with Multiple Tumor Suppressor Gene Defects but Inhibition of Tumorigenicity is Accomplished by Correction of Any Single Defect via Chromosome Transfer," <i>Molecular and Cellular Biology</i> , 12(3):1387-1395, 1992.	
<i>CSU</i>	C45	GREEN, "When the Products of Oncogenes and Anti-Oncogenes Meet," <i>Cell</i> , 56:1-3, 1989.	

EXAMINER

*low*

DATE CONSIDERED

*26 Mar 2003*

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

Sheet

6

of

15

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
<i>CLC</i>	C46	GREGORY <i>et al.</i> , "Tumor Suppressor of Gene Thereapy of Cancer: Adenoviral Mediated Gene Transfer of p53 into Human Tumor Cell Lines," <i>J. Cell. Biochem. Supp.</i> 18a, p. 237. <i>C1994</i>	
	C47	GRIDLEY <i>et al.</i> , "Evaluation of Reaiation Effects Against C6 Glioma in Combination with Vaccinia Virus-p53 Gene Therapy," <i>International J. Oncology</i> , 12:1093-1098, 1998.	
	C48	GRIEP and WESTPHAL, "Antisense Myc Sequences Induce Differentiation of F9 Cells," <i>Proc. Natl. Acad. Sci. USA</i> , 85:6806-6810, 1988.	
	C49	GUNNING <i>et al.</i> , "A Human $\beta$ -Actin Expression Vector System Directs High-Level Accumulation of Antisense Transcripts," <i>Proc. Natl. Acad. Sci. USA</i> , 84:4831-4835, 1987.	
	C50	GUSTERSON <i>et al.</i> , "Expression of p53 in Premalignant and Malignant Squamous Epithelium," <i>Oncogene</i> , 6:1785-1798, 1991.	
	C51	GUTIERREZ <i>et al.</i> , "Gene Therapy for Cancer," <i>The Lancet</i> , 339:715-721, 1992.	
	C52	HANANIA <i>et al.</i> , "Genetic Chemoprotection of Hematopoietic Cells and Genetic Chemosensitization of Breast Cancer Cells in a Mouse Cancer Gene Therapy Model," <i>Proc. Amer. Assoc. Cancer Res.</i> , Vol. 37, #2362, March 1996.	
	C53	HARPER <i>et al.</i> , "The p21 cdk-Interacting Protein cip 1 is a Potent Inhibitor of g1 Cyclin-Dependent Kinases," <i>Cell</i> , 75:805-816, 1993.	
	C54	HARPER <i>et al.</i> , "Enhancement of Antitumor Effects of p53 Gene Therapy by Combination with DNA-Damaging Agents" <i>Cancer Gene Therapy</i> , Vol. 3, 6, Conf. Suppl., S41-42, 1996.	
	C55	HECHT <i>et al.</i> , "Comparison of Wildtype and Mutated p53 Protein Expression Induced by UV Irradiation of Cultured Cells," <i>FASEB Journal</i> , 8:A667, #3870, 1994.	
	C56	<i>Hematology/Oncology Clinics of North America</i> , v.4, n.3, Bone Marrow Transpantation, edited by Stephen J. Foreman, M.D., 1990. <i>pages iv- ix.</i>	
	C57	HINDS <i>et al.</i> , "Mutation is Required to Activate the p53 Gene for Cooperation with the <i>ras</i> Oncogene and Transformation," <i>Journal of Virology</i> , 63(2):739-746, February 1989.	
<i>CLC</i>	C58	HINDS <i>et al.</i> , "The p53 Proto-Oncogene Can Suppress Transformation by Other Oncogenes, and Mutations in the Proto-Oncogene Can Activate the Gene for Transformation," <i>In: Common Mechanisms of Transformation by Small DNA Tumor Viruses</i> , Luis P. Villarreal (ed.), Chapter 7, pp. 83-101, 1989.	


EXAMINER

*low*

DATE CONSIDERED

*26 Mar 2003*

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

Sheet 7 of 15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset <i>et al.</i>
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

RECEIVED  
MAR 26 2003  
C.C. CENTER 160012908

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CBK	C59	HINDS, "Biological Consequences of Mutation of the p53 Proto-Oncogene," <i>UMI Dissertation Services</i> , October 1989. (ABSTRACT ONLY).	
	C60	HITT <i>et al.</i> , "Adenovirus E1A Under the Control of Heterologous Promoters: Wide Variation in E1A Expression Levels Has Little Effect on Virus Replication," <i>Virology</i> , 179:667-678, 1990.	
	C61	HODGSON, "Advances in Vector Systems for Gene Therapy," <i>Exp. Opin. Ther. Patents</i> , 5(5):549-468, 1995.	
	C62	HOLLSTEIN <i>et al.</i> , "p53 Mutations in Human Cancers," <i>Science</i> , 253:49-53, 1991.	
	C63	HUANG <i>et al.</i> , "Suppression of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells," <i>Science</i> , 242:1563-1566, December 1988.	
	C64	HUBER <i>et al.</i> , "Retroviral-Mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8039-8043, 1991.	
	C65	IJIRI, "Apoptosis (cell death) Induced in Mouse Bowel by 1,2-Dimethylhydrazine, Methylazoxymethanol Acetate and $\gamma$ -Rays," <i>Cancer Research</i> , 49:6342-6346, 1989.	
	C66	IZANT AND WEINTRAUB "Inhibition of Thymidine Kinase Gene Expression by Anti-Sense RNA: A Molecular Approach to Genetic Analysis," <i>Cell</i> , 36:1007-1015, 1984.	
	C67	JAFFE <i>et al.</i> , "Adenovirus-Mediated <i>In Vivo</i> Gene Transfer and Expression in Normal Rat Liver," <i>Nature Genetics</i> , 1:372-378, 1992.	
	C68	JOHNSON <i>et al.</i> , "Transfection of a Rat Cell Line with the v-Ki-ras Oncogene is Associated with Enhanced Susceptibility to Natural Killer Cell Lysis," <i>J. Exp. Med.</i> , 162:1732-1737, 1985.	
	C69	KANEKO <i>et al.</i> , "Induction Of Apoptosis and p53 Protein By Adriamycin and Hyperthermia In A Rat Mammary Adenocarcinoma Cell Line," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:314, #1871, 1994.	
	C70	KASID <i>et al.</i> , "Effect of Antisense <i>c-raf-1</i> on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma," <i>Science</i> , 243:1354-1356, 1989.	
	C71	KASTAN <i>et al.</i> , "p53 and Other Molecular Controls of the Response to DNA Damage," <i>J. Cell. Biochem.</i> , 9(18C):164, 1994.	
CBK	C72	KASTAN, "Discussion of Dr. Kastan's Presentation," <i>Adv. Exp. Med. Biol.</i> , 339:295-296, 1993.	

EXAMINER


low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).





**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN	
Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset <i>et al.</i>
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

TECH CENTER 1600/2900

MAR 26 2003


RECEIVED

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CSF	C73	KASTAN, "p53: a Determinant of the Cell Cycle Response to DNA Damage," <i>Adv. Exp. Med. Biol.</i> , 339:291-293, 1993.	
CSF	C74	KEMP <i>et al.</i> , "p53-Deficient Mice Are Extremely Susceptible To Radiation-Induced Tumorigenesis," <i>Nature Genetics</i> , 8(1):66-69, 1994.	
	<del>C75</del>	<del>KHOKHA, Rama <i>et al.</i>, "Antisense RNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss3T3 Cells," <i>Science</i>, 243:947-950, 1989.</del>	
CSF	C76	KLESSIG <i>et al.</i> , "Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenovirus Gene Whose Product is Toxic to the Recipient Human Cell," <i>Molecular and Cellular Biology</i> , 4(7): 1354-1362, July 1984.	
	C77	KLINKEN <i>et al.</i> , "Transcriptional and Post-Transcriptional Regulation of C-MYC C-MYB and p53 During Proliferation and Differentiation of Muring Erythroleukemia Cells Treated with DFMO and DMSO," <i>Exp. Cell Res.</i> , 178:185-198, 1988.	
	C78	KMIEC, "Investigators Have Been Searching For Ways To Add Corrective Genes To Cells Harboring Defective Genes. A Better Strategy Might Be To Correct The Defects." <i>American Scientist</i> , 87:240-247, 1999.	
	C79	KRIEGLER <i>et al.</i> , In: Gene Transfer and Expression: a Laboratory Manual, 1990.	
CSF	C80	KRIS <i>et al.</i> , "Expression of K-Ras Oncogene in Tumor Cell Variants Exhibiting Different Metastatic Capabilities," <i>Int. J. Cancer</i> , 35:227-230, 1985.	
	<del>C81</del>	<del>KUMAR <i>et al.</i>, "Activation of ras Oncogenes Preceding the Onset of Neoplasia," <i>Science</i>, 248:1101-1104, 1990.</del> <i>Reference Not provided</i>	
CSF	C82	LAMB AND CRAWFORD, "Characterization of the Human p53 Gene," <i>Molecular and Cellular Biology</i> , 6(5):1379-1385, May 1986.	
	C83	LANE, "A Death in the Life of p53," <i>Nature</i> , 362:786-787, 1993.	
	C84	LE GAL LA SALLE <i>et al.</i> , "An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain," <i>Science</i> , 259:988-990, 1993.	
	C85	LEE AND BERNSTEIN, "p53 Mutations Increase Resistance to Ionizing Radiation," <i>Proc. Natl. Acad. Sci. USA</i> , 90(12):5742-5746, 1993.	
CSF	C86	LEE <i>et al.</i> , "Molecular Basis of Tumor Suppression by the Human Retinoblastoma gene," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 <sup>th</sup> Annual Meeting, Supplement 14C, #1 001, 1990.	

EXAMINER  Low	DATE CONSIDERED  26 Mar 2003
---------------------	------------------------------------

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).





**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

TECH CENTER 1600/2900

MAR 26 2003

RECEIVED

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the work (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
2	C87	<del>LESOON WOOD et al., "Systemic Gene Therapy with a Liposome p53 Complex Reduces the Growth and Metastases of a Malignant Human Breast Cancer in Nude Mice," Proc. Annu. Meet. Am. Assoc. Cancer Res., Vol. 36, pp. A2509, 1995.</del> <i>Reference Not Provided</i>	
189	C88	LEVINE et al., "The p53 Growth Suppressor Gene," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 <sup>th</sup> Annual Meeting, Supplement 14C:264, #1 030, 1990.	
	C89	LEVINE et al., "The 1993 Walter Hubert Lecture: the Role of the p53 Tumour-Suppressor Gene in Tumorigenesis," <i>Br. J. Cancer</i> , 69(3):409-416, 1994.	
	C90	LEVINE et al., "The p53 Growth Suppressing Gene Can Inhibit Transformation by Other Oncogenes," <i>The Journal of Cell Biology</i> , The American Society for Cell Biology, Twenty-ninth Annual Meeting, Houston, Texas, November 5-9, 1989, Abstract 502.	
	C91	LOGANZO, Jr. et al., "Stabilization of p53 Protein is a Critical Response to UV Radiation in Human Melanocytes: Implications for Melanoma Development," <i>Mol. Cell. Differ.</i> , 2(1):23-43, 1994.	
	C92	LORD et al., "Macrophage Inflammatory Protein: Its Characteristics, Biological Properties and Role in the Regulation of Haemopoiesis," <i>International J. of Hematology</i> , 57:197-206, 1993.	
	C93	LOTEM AND SACHS, "Regulation by <i>bcl-2</i> , <i>c-myc</i> , and p53 of Susceptibility to Induction of Apoptosis by Heat Shock and Cancer Chemotherapy Compounds in Differentiation-Competent and Defective Myeloid Leukemic Cells," <i>Cell Growth Differ.</i> , 4(1):41-47, 1993.	
	C94	MAITY et al., "The Molecular Basis for Cell Cycle Delays Following Ionizing Radiation: a Review," <i>Radiother. Oncol.</i> , 31(1):1-13, 1994.	
	C95	MALKIN et al., "Mutant p53 Confers Tumorigenicity to a Cell Line Lacking p53: Evidence for a Second p53 Function in Tumor Formation," <i>Blood</i> , 76(10, Suppl. 1):238a, Abstract 944, 1990.	
	C96	MARSHALL, "Gene Therapy's Growing Pains," <i>Science</i> , 269:1050-1055, 1995.	
	C97	MARX, "Cell Death Studies Yield Cancer Clues," <i>Science</i> , 259:760-761, 1993.	
CSU	C98	MAXWELL et al., "Inefficiency of Expression of Luciferase Reporter from Transfected Murine Leukaemia Proviral DNA May Be Partially Overcome by Providing a Strong Polyadenylation Signal," <i>Journal of General Virology</i> , 72:1721-1724, 1991.	


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

Sheet 10 of 15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

RECEIVED  
MAR 26 2003  
TECH CENTER 160012900

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
C89	C99	McGRATH et al., "Structure and Organization of the Human <i>Ki-ras</i> Protooncogene and a Related Processed Pseudogene," <i>Nature</i> , 304:501, 1983.	
	<del>C100</del>	<del>McGRATH et al., "Tumor-Specific Antisense Oligonucleotides for Controlling Cancer," Abstract No. 114:5578n, Chemical Abstracts, 114(7):68, 1991.</del>	
C89	C101	McILWRATH et al., "Cell Cycle Arrests and Radiosensitivity of Human Tumor Cell Lines: Dependence on Wild-Type p53 for Radiosensitivity," <i>Cancer Res.</i> , 54(14):3718-3722, 1994.	
	C102	MERCER et al., "Antiproliferative Effects of Wild Type Human p53," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 <sup>th</sup> Annual Meeting, Supplement 14C:264, #1 029, 1990.	
	C103	MERCER, "Cell Cycle Regulation and the p53 Tumor Suppressor Protein," <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2(3):251-263, 1992.	
	C104	MERCOLA et al., "Antisense RNA: Eukaryotic Controls," <i>Gene</i> , 72:253-265, 1988.	
	C105	MILLER AND VILE, "Targeted Vectors for Gene Therapy," <i>FASEB Journal</i> , 9:190-199, 1995.	
	C106	MINNA et al., "The Molecular Pathogenesis of Lung Cancer Involves the Accumulation of a Large Number of Mutations in Dominant Oncogenes and Multiple Tumor Suppressor Genes (Recessive Oncogenes)," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 <sup>th</sup> Annual Meeting, Supplement 14C:264, #1 003, 1990.	
	C107	MIYAKE et al., "Enhancement of Chemosensitivity in Human Bladder Cancer Cells by Adenoviral-Mediated p53 Gene Transfer," <i>Anticancer Res.</i> , 18:3087-92, 1998.	
	C108	MONTENARH, "Biochemical, Immunological, and Functional Aspects of the Growth-Suppressor/Oncoprotein p53," <i>Critical Reviews in Oncogenesis</i> , (3):233-256, 1992.	
	C109	MUKHOPADHYAY et al., "Specific Inhibition of <i>K-ras</i> Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA," <i>Cancer Research</i> , 51:1744-1748, 1991.	
C89	C110	MUNROE, "Antisense RNA Inhibits Splicing of Pre-mRNA <i>In Vitro</i> ," <i>The EMBO Journal</i> , 7(8):2523-2532, 1988.	


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

RECEIVED  
MAR 25 2003  
FBI CENTER 1600/2900

MAR 25 2003

RECEIVED

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CSA	C111	NABEYA et al., "The Mutational Status of p53 Protein in Gastric Cancer Cell Lines Predicts Sensitivity to Chemotherapeutic Agents," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:602, Abstract #3591, 1994.	
	C112	NEVE, "Adenovirus Vectors Enter the Brain," <i>Trends Neuroscience</i> , 16(7):251-253, 1993.	
	C113	NGUYEN et al., "Delivery of the p53 Tumor Suppressor Gene into Lung Cancer Cells by an Adenovirus/DNA Complex," <i>Cancer Gene Therapy.</i> , 4(3):191-198, 1997.	
	C114	NIELSEN et al., "Efficacy of p53 Adenovirus-Mediated Gene Therapy Against Human Bbreast Cancer Xenografts," <i>Pro. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 37, pp. A2317, 1996.	
	C115	O'CONNOR et al., "Relationship between p53, Cyclin E-cdk2 Kinase Complexes and G1 Arrest Induced by Ionizing Radiation in Human Cells," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:635, Abstract #3785, 1994.	
	C116	OGAWA et al., "Novel Combination Therapy For Human Colon Cancer With Adenovirus-Mediated Wild-Type p53 Gene Transfer and DNA-Damaging Chemotherapeutic Agent," <i>Int. J. Cancer</i> , 73:367-370, 1997.	
	C117	ORAZI et al., "Frequent p53 Overexpression in Therapy Related Myelodysplastic Syndromes and Acute Myeloid Leukemias: an Immunohistochemical Study of Bone marrow Biopsies," <i>Mod. Path.</i> , 6:521-525, 1993.	
	C118	ORKIN, et al, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," December 7, 1995	
	C119	OWENS AND BOYD, "Expressing Antisense Po RNA in Schwann Cells Perturbs Myelinatino," <i>Development</i> , 112:639-649, 1991.	
✓ gel	C120	PALMER et al., "Efficient Retrovirus-Mediated Transfer and Expression of a Human Adenosine Deaminase Gene in Diploid Skin Fibroblasts from an Adenosine Deaminase-Deficient Human," <i>Proceedings of the National Academy of Science USA</i> , 84:1055-1059, 1987.	
	<del>C121</del>	<del>PAULL et al., "The Synthesis of XTT: a New Tetrazolium Reagent that is Bireducible to a Water-Soluble Formazan," <i>J. Heterocyclic Chem.</i>, 25:911-914, 1988. Reference Not Provided</del>	
gel	C122	PFARR et al., "Differential Effects of Polyadenylation Regions on Gene Expression in Mammalian Cells," <i>DNA</i> , 5(2):115-122, 1986.	


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

Sheet 12 of 15

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.
CSU	C123	PIROLLO et al., "p53 Mediated Sensitization of Squamous Cell Carcinoma of Head and Neck to Radiotherapy," <i>Oncogene</i> , 14:1735-46, 1997.
CSU	C124	PREVEC et al., "Use of Human Adenovirus-Based Vectors for Antigen Expression in Animals," <i>J Gen. Virol.</i> , 70:429-434, 1989.
	<del>C125</del>	<del>Proceedings of the American Association for Cancer Research, Vol. 36, p. 21, March 1995. Reference Not provided</del>
CSU	C126	PROCHOWNIK et al., "c-myc Antisense Transcripts Accelerate Differentiation and Inhibit G <sub>1</sub> Progression in Murine Erythroleukemia Cells," <i>Molecular and Cellular Biology</i> , 8(9):3683-3695, 1988.
	C127	RAJAN et al., "Simian Virus 40 Small-t Does Not Transactivate RNA Polymerase II Promoters in Virus Infections," <i>J. Virology</i> , 65(12):6553-6561, 1991.
	C128	RAU et al., "Response of p53 to Treatment with Actinomycin D in Human Mammary Carcinoma Cell Lines," <i>J. Cancer Res. Clin. Oncol.</i> , 120:R108, 1994.
	C129	ROSENFELD et al., "Adenovirus-Mediated Transfer of a Recombinant $\alpha_1$ -Antitrypsin Gene to the Lung Epithelium <i>In Vivo</i> ," <i>Science</i> , 252:431-434, 1991.
	C130	ROSENFELD et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," <i>Cell</i> , 68:143-155, 1992.
CSU	C131	ROSS et al., "Gene Therapy in the United States: A Five-Year Status Report," <i>Human Gene Therapy</i> , 7:1781-1790, 1996.
over this abstract	<del>C132</del>	<del>ROTH, "Gene Replacement Strategies for Therapy and Prevention of Lung Cancer," <i>Proceedings Annual Meeting of American Assoc. Cancer Res.</i>, 35:692-3, 1994. Duplicate of IDS Filed 18 Dec 2002</del>
CSU	C133	RYAN et al., "Cell Cycle Analysis of p53-Induced Cell Death in Murine Erythroleukemia Cells," <i>Mol. Cell. Biol.</i> , 13:711-719, 1993.
	C134	SAGER, "Tumor Suppressor Genes: The Puzzle and the Promise," <i>Science</i> , 246:1406-1412, December 1989.
	C135	SANTHANAM et al., "Repression of the Interleukin 6 Gene Promoter by p53 and the Retinoblastoma Susceptibility Gene Product," <i>Proc. Natl. Acad. Sci. USA</i> , 88:7605-7609, 1991.
CSU	C136	SANTOS et al., "Malignant Activation of a K-ras Oncogene in Lung Carcinoma but Not in Normal Tissue of the Same Patient," <i>Science</i> , 223:661-664, 1984.


EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

Sheet 13 of 15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

TECH CENTER 1600/2900

MAR 26 2003

RECEIVED

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CSF	C137	SCHULER et al., "A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer," <i>Human Gene Therapy</i> , 9:2075-2082, 1998.	
	C138	SEYAMA et al., "In Vitro and In Vivo Regulation of Liver Epithelial Cells Carrying a Metallothionein-ras T24 Fusion Gene," <i>Molecular Carcinogenesis</i> , 1:89-95, 1988.	
	C139	SHAW et al., "Induction of Apoptosis by Wild-Type p53 in a Human Colon Tumor-Derived Cell Line," <i>Proc. Natl. Acad. Sci. USA</i> , 89(10):4495-4499, 1992.	
	C140	SHENK, "Group C Adenoviruses as Vectors for Gene Therapy," in <i>Viral Vectors</i> , 1995, Academic Press.	
	C141	SHIMIZU et al., "Structure of the <i>Ki-ras</i> Gene of the Human Lung Carcinoma Cell Line Calu-1," <i>Nature</i> , 304:497-500, 1983.	
	C142	SLICHENMYER et al., "Loss of p53-Associated G1 Checkpoint Does Not Decrease Cell Survival following DNA Damage," <i>Cancer Research</i> , 53:4164-4168, 1993.	
CSF	C143	SPITZ et al., "Adenoviral mediated p53 gene therapy enhances radiation sensitivity of colorectal cancer cell lines," <i>Proc. Amer. Assoc. Cancer Res.</i> , Vol. 37, #2366, March 1996.	
	C144	<del>STEEL, "Cyclins and Cancer: Wheels Within Wheels," <i>Lancet</i>, 343:931-932, 1994. Previously cited PTO 1449 (16 Feb 1995).</del>	
CSF	C145	STEIN et al., "Antisense Oligonucleotides as Therapeutic Agents - is the Bullet Really Magical?" <i>Science</i> , 261:1004-1012, 1993.	
	C146	STOWERS et al., "Activation of the <i>K-ras</i> Protooncogene in Lung Tumors from Rats and Mice Chronically Exposed to Tetranitromethane," <i>Cancer Research</i> , 47:3212-3219, 1987.	
	C147	STRATAGENE CATALOGUE, page 39, 1988.	
	C148	STRATFORD-PERRICAUDET, "Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector," <i>Human Gene Therapy</i> , 1:241-256, 1990.	
	C149	STRATFORD-PERRICAUDET, "Feasibility of Adenovirus-Mediated Gene Transfer <i>In Vivo</i> ," <i>Bone Marrow Transplantation</i> , 9(Suppl. 1):151-152, 1992.	
CSF	C150	STRATFORD-PERRICAUDET, "Gene Transfer into Animals: the Promise of Adenovirus," <i>Human Gene Transfer</i> , 219:51-61, 1991.	


EXAMINER

low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

Sheet 14 of 15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

TECH CENTER 1600/2903

MAR 26 2003

RECEIVED

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
CSE	C151	STRATFORD-PERRICAUDET, "Widespread Long-Term Gene Transfer to Mouse Skeletal Muscles and Heart," <i>J. Clin. Invest.</i> , 90:626-630, 1992.	
	C152	SU et al., "Transformation and Radiosensitivity of Human Diploid Skin Fibroblasts Transfected with SV40 T-Antigen Mutants Defective in RB and p53 Binding Domains," <i>Int. J. Radiat. Biol.</i> , 62(4):461-468, 1992.	
	C153	SUNDARESAN et al., "Somatic Genetic Changes in Pre-Invasive Lesions in Bronchial Epithelium," ABSTRACT, <i>J. Pathol.</i> , 167(Suppl):100A, 1992.	
	C154	TAKAYAMA et al., "Growth Suppression of Lung Cancer by Recombinant Adenovirus-Mediated Human p53 and p21 cDNA Transfer," <i>Proceedings Annual Meeting, American Society of Clinical Oncology</i> , 16: A1597, 1997.	
	C155	TANG et al., "Potential Application of Gene Therapy to Lung Cancer," <i>Seminars in Oncology</i> , 20(4):368-373, 1993.	
	C156	TAYA et al., "A Novel Combination of <i>K-ras</i> and <i>myc</i> Amplification Accompanied by Point Mutational Activation of <i>K-ras</i> in a Human Lung Cancer," <i>The EMBO Journal</i> , 3(12):2943-2946, 1984.	
	C157	TISHLER, et al, "Increases in Sequence Specific DNA Binding by p53 Following Treatment with Chemotherapeutic and DNA Damaging Agents, <i>Cancer Research</i> , 53:2212-2216, 1993.	
	C158	TOFTGARD et al., "Proto-Oncogene Expression During Two-Stage Carcinogenesis in Mouse Skin," <i>Carcinogenesis</i> , 6(4):655-6657, 1985.	
	C159	TSENG AND BROWN, "Antisense Oligonucleotide Technology in the Development of Cancer Therapeutics," <i>Cancer Gene Therapy</i> , 1(1):65-71, 1994.	
	C160	VARGHESE et al., "The Role of p53 and <i>ras</i> Genes in Radiation-Induced Transformation of Immortalized Human Epidermal Keratinocytes," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:91, Abstract #542, 1994.	
	C161	VERMA et al, "Gene Therapy - Promises, Problems, and Prospects," <i>Nature</i> , 389:239-242, 1997	
	C162	VOGELSTEIN et al., "Genetic Alterations Accumulate During Colorectal Tumorigenesis," UCLA Symposia on Molecular and Cellular Biology, February 3 - March 11, 1990, Abstracts, 19 <sup>th</sup> Annual Meeting, <i>J. Cell. Biochem.</i> , Supplement 14C:264, #I 004, 1990.	
CSE	C163	VOGELSTEIN et al., "Genetic Alterations During Colorectal-Tumor Development," <i>The New England Journal of Medicine</i> , 319(9):525-532, 1988.	


EXAMINER

low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

Sheet 15 of 15

COMPLETE IF KNOWN

Application Number	08/335,461
Confirmation Number	
Filing Date	November 7, 1994
First Named Inventor	Ruth Gjerset et al.
Group Art Unit	1653
Examiner Name	Christopher S. F. Low
Attorney Docket No.	54763.8001.US02

JH CENTER 1600/2900

MAR 26 2003

RECEIVED

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	<del>C164</del>	<del>WAHRAN et al., Tumour Biol. 6:41-56, 1985. Document not provided</del>	
C88	C165	WANG AND FINER, "Second-Generation Adenovirus Vectors," <i>Nature Medicine</i> , 2:714-716, June 6, 1996.	
	C166	WEINBERG, "Tumor Suppressor Genes," <i>Science</i> , 254:1138-1146, 1991.	
	C167	WILKINSON et al., "Constitutive and Enhanced Expression from the CMV Major IE Promoter in a Defective Adenovirus Vector," <i>Nucleic Acids Research</i> , 20(9):2233-2239, 1992.	
	C168	WILLS AND MENZEL, "Adenovirus Vectors for Gene Therapy of Cancer," <i>Journal of Cellular Biochemistry</i> , Supp. 17E, p. 204, Abstract #S216, March-April 1993.	
	C169	WILLS et al., "Tumor Suppressor Gene Therapy of Cancer: Adenoviral Mediated Gene Transfer of p53 and Retinoblastoma cDNA into Human Tumor Cell Lines," <i>J. Cell. Biochem. Supp.</i> 18c, p. 204. (1994)	
	C170	WINTER AND PERUCHO, "Oncogene Amplification During Tumorigenesis of Established Rat Fibroblasts Reversibly Transformed by Activated Human ras Oncogenes," <i>Molecular and Cellular Biology</i> , 6(7):2562-2570, 1986.	
C84	C171	XU et al., "Parental Gene Therapy with p53 Inhibits Human Breast Tumors In Vivo Through a Bystander Mechanism Without Evidence of Toxicity," <i>Human Gene Therapy</i> , 8:177-185, 1997.	
X	<del>C172</del>	<del>YAMADA AND OHYAMA, "Radiation and Apoptosis," <i>Gan To Kagaku Ryoho</i>, 21(5):602-607, 1994. (Japanese Language Document)</del>	
C84	C173	ZHANG AND ROTH, "Propagation of Recombinant p53 Adenovirus and Evaluation of its Effect on Human Lung Cancer Cell Lines," <i>The Fourth Meeting of the Molecular Basis of Cancer</i> , June 1993.	
X	<del>C174</del>	<del>ZHANG et al., "Generation and Identification of Recombinant Adenovirus by Liposome-Mediated Transfection and PCR Analysis," <i>BioTechniques</i>, 15(5):868-872, 1993. Reference Not provided</del>	
	<del>C175</del>	<del>ZHANG et al., "High-Efficiency Gene Transfer and High Level Expression of Wild-Type p53 in Human Lung Cancer Cells Mediated by Recombinant Adenovirus," <i>Cancer Gene Therapy</i>, 1:5-13, 1994. Reference Not provided.</del>	
C84	C176	ZHOU AND DUESBERG, "myc Protooncogene Linked to Retroviral Promoter, but Not the Enhancer, Transforms Embryo Cells," <i>Proceedings of the National Academy of Science USA</i> , 85:2924-2928, 1988.	

EXAMINER

Low

DATE CONSIDERED

26 Mar 2003

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).